文献速递骨软组织肉瘤与黑色素瘤

纳武利尤单抗单药治疗的安全性特征:晚期黑色素瘤患者的汇总分析

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
PubMed 文献 · J Clin Oncol · 2016-11-14

该回顾性汇总分析纳入4项研究共576例接受纳武利尤单抗3 mg/kg每2周一次的晚期黑色素瘤患者,评估治疗相关不良事件及特定免疫相关不良事件的发生率、发生与缓解时间及其对抗肿瘤疗效的影响。结果显示71%发生任何级别治疗相关不良事件,10%发生3至4级,未报告药物相关死亡;特定不良事件发生率为49%,多数经既定安全指南管理后缓解,使用免疫调节剂未影响客观缓解率。

要点

  • 576例中71%发生任何级别治疗相关不良事件,10%发生3至4级,未报告药物相关死亡。
  • 特定免疫相关不良事件发生于49%患者,3至4级占4%,中位发生时间5至15周。
  • 发生任何级别特定不良事件者客观缓解率显著更高,但无无进展生存获益。

核心结论

  • 纳武利尤单抗单药治疗相关不良事件以低级别为主,多数经既定安全指南管理后缓解。
  • 使用免疫调节剂未影响客观缓解率,但任何级别治疗相关特定不良事件与更高客观缓解率相关,而无无进展生存获益。

研究设计与样本

  • 回顾性汇总分析,纳入4项研究(含2项III期试验)的晚期黑色素瘤患者,接受纳武利尤单抗3 mg/kg每2周一次,共576例。

主要发现

  • 71%(95%CI 67%至75%)发生任何级别治疗相关不良事件,最常见为疲乏(25%)、瘙痒(17%)、腹泻(13%)和皮疹(13%)。
  • 10%(95%CI 8%至13%)发生3至4级治疗相关不良事件,未报告药物相关死亡。
  • 特定不良事件发生于49%患者,最常见为皮肤、胃肠道、内分泌和肝脏相关;3至4级特定不良事件发生于4%患者。
  • 特定不良事件中位发生时间从皮肤相关5周至肾脏相关15周不等。
  • 约24%患者接受全身免疫调节剂处理特定不良事件,多数病例缓解。

关键数值与推荐

  • 调整给药次数后,发生任何级别治疗相关特定不良事件的患者客观缓解率显著高于未发生者。
  • 接受与未接受全身免疫调节剂的患者客观缓解率相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose We conducted a retrospective analysis to assess the safety profile of nivolumab monotherapy in patients with advanced melanoma and describe the management of adverse events (AEs) using established safety guidelines. Patients and Methods Safety data were pooled from four studies, including two phase III trials, with patients who received nivolumab 3 mg/kg once every 2 weeks. We evaluated rate of treatment-related AEs, time to onset and resolution of select AEs (those with potential immunologic etiology), and impact of select AEs and suppressive immune-modulating agents (IMs) on antitumor efficacy. Results Among 576 patients, 71% (95% CI, 67% to 75%) experienced any-grade treatment-related AEs (most commonly fatigue [25%], pruritus [17%], diarrhea [13%], and rash [13%]), and 10% (95% CI, 8% to 13%) experienced grade 3 to 4 treatment-related AEs. No drug-related deaths were reported. Select AEs (occurring in 49% of patients) were most frequently skin related, GI, endocrine, and hepatic; grade 3 to 4 select AEs occurred in 4% of patients. Median time to onset of select AEs ranged from 5 weeks for skin to 15 weeks for renal AEs. Approximately 24% of patients received systemic IMs to manage select AEs, which in most cases resolved. Adjusting for number of doses, objective response rate (ORR) was significantly higher in patients who experienced treatment-related select AEs of any grade compared with those who did not. ORRs were similar in patients who did and patients who did not receive systemic IMs. Conclusion Treatment-related AEs with nivolumab monotherapy were primarily low grade, and most resolved with established safety guidelines. Use of IMs did not affect ORR, although treatment-related select AEs of any grade were associated with higher ORR, but no progression-free survival benefit.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Weber JS, Hodi FS, Wolchok JD, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2016. PMID: 28068177. doi:10.1200/JCO.2015.66.1389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。